GlaxoSmithKline Forecast, price target & analysts
GlaxoSmithKline Target price 2025 - Analyst rating & recommendation
GlaxoSmithKline Classifications & Recommendation:
GlaxoSmithKline Price Target
| Target Price | GBP15.35 |
| Price | GBP14.06 |
| Potential |
9.22%
register free of charge
|
| Number of Estimates | 24 |
|
24 Analysts have issued a price target GlaxoSmithKline 2026 .
The average GlaxoSmithKline target price is GBP15.35.
This is
9.22%
register free of charge
GBP27.62
96.48%
register free of charge
GBP11.82
15.92%
register free of charge
|
|
| A rating was issued by 31 analysts: 5 Analysts recommend GlaxoSmithKline to buy, 16 to hold and 10 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the GlaxoSmithKline stock has an average upside potential 2026 of
9.22%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion GBP | 31.38 | 33.48 |
| 3.46% | 6.70% | |
| EBITDA Margin | 26.11% | 33.62% |
| 5.46% | 28.77% | |
| Net Margin | 8.21% | 21.43% |
| 49.49% | 161.12% |
26 Analysts have issued a sales forecast GlaxoSmithKline 2025 . The average GlaxoSmithKline sales estimate is
This results in the following potential growth metrics:
21 Analysts have issued an GlaxoSmithKline EBITDA forecast 2025. The average GlaxoSmithKline EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
24 GlaxoSmithKline Analysts have issued a net profit forecast 2025. The average GlaxoSmithKline net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share GBP | 0.62 | 1.73 |
| 48.33% | 179.03% | |
| P/E | 8.12 | |
| EV/Sales | 2.10 |
24 Analysts have issued a GlaxoSmithKline forecast for earnings per share. The average GlaxoSmithKline EPS is
This results in the following potential growth metrics and future valuations:
GlaxoSmithKline...
Current GlaxoSmithKline Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Shore Capital |
Locked
➜
Locked
|
Locked | Apr 30 2025 |
| JP Morgan Cazenove |
Locked
➜
Locked
|
Locked | Mar 28 2025 |
| JP Morgan Cazenove |
Locked
➜
Locked
|
Locked | Jan 07 2025 |
| JP Morgan Cazenove |
Locked
➜
Locked
|
Locked | Dec 11 2024 |
| Berenberg Bank |
Locked
➜
Locked
|
Locked | Nov 29 2024 |
| Berenberg Bank |
Locked
➜
Locked
|
Locked | Sep 10 2024 |
| Deutsche |
Locked
➜
Locked
|
Locked | Sep 03 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Shore Capital:
Locked
➜
Locked
|
Apr 30 2025 |
|
Locked
JP Morgan Cazenove:
Locked
➜
Locked
|
Mar 28 2025 |
|
Locked
JP Morgan Cazenove:
Locked
➜
Locked
|
Jan 07 2025 |
|
Locked
JP Morgan Cazenove:
Locked
➜
Locked
|
Dec 11 2024 |
|
Locked
Berenberg Bank:
Locked
➜
Locked
|
Nov 29 2024 |
|
Locked
Berenberg Bank:
Locked
➜
Locked
|
Sep 10 2024 |
|
Locked
Deutsche:
Locked
➜
Locked
|
Sep 03 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
